Clinical Trial: Camrelizumab combined with chemotherapy plus ¹⁸F-FDG PET-CT screening for stage II esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy or surgery (China)

Posted On: 2026-08-11

China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Camrelizumab combined with chemotherapy plus ¹⁸F-FDG PET-CT screening for stage II esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy or surgery'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129557

Registration Time: 2026/08/06

Type: Interventional study

Primary Sponsor: Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=333786

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Camrelizumab combined with chemotherapy plus ¹⁸F-FDG PET-CT screening for stage II esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy or surgery (China)